OBJECTIVE: To determine the safety and effects on @entity2690 secretion of umbilical cord (UC) mesenchymal stromal cells (MSCs) plus autologous bone marrow mononuclear cell (aBM-MNC) @entity8 ( @entity8 ) without immunotherapy in established @entity1723 ( @entity1723 ). RESEARCH DESIGN AND METHODS: Between January 2009 and December 2010, 42 @entity1 with @entity1723 were randomized (n = 21/group) to either @entity8 (1.1 * 10(6)/kg UC-MSC, 106.8 * 10(6)/kg aBM-MNC through supraselective pancreatic artery cannulation) or standard care (control). @entity1 were followed for 1 year at 3-month intervals. The primary end point was C-peptide area under the curve (AUCC-Pep) during an oral @entity413 tolerance test at 1 year. Additional end points were safety and tolerability of the procedure, metabolic control, and quality of life. RESULTS: The treatment was well tolerated. At 1 year, metabolic measures improved in treated @entity1 : AUCC-Pep increased 105.7% (6.6    6.1 to 13.6    8.1 pmol/mL/180 min, P = 0.00012) in 20 of 21 responders, whereas it decreased 7.7% in control subjects (8.4    6.8 to 7.7    4.5 pmol/mL/180 min, P = 0.013 vs. @entity8 ); @entity2690 area under the curve increased 49.3% (1,477.8    1,012.8 to 2,205.5    1,194.0 mmol/mL/180 min, P = 0.01), whereas it decreased 5.7% in control subjects (1,517.7    630.2 to 1,431.7    441.6 mmol/mL/180 min, P = 0.027 vs. @entity8 ). @entity4051 c decreased 12.6% (8.6    0.81% [70.0    7.1 mmol/mol] to 7.5    1.0% [58.0    8.6 mmol/mol], P < 0.01) in the treated group, whereas it increased 1.2% in the control group (8.7    0.9% [72.0    7.5 mmol/mol] to 8.8    0.9% [73    7.5 mmol/mol], P < 0.01 vs. @entity8 ). Fasting glycemia decreased 24.4% (200.0    51.1 to 151.2    22.1 mg/dL, P < 0.002) and 4.3% in control subjects (192.4    35.3 to 184.2    34.3 mg/dL, P < 0.042). Daily @entity2690 requirements decreased 29.2% in only the treated group (0.9    0.2 to 0.6    0.2 IU/day/kg, P = 0.001), with no change found in control subjects (0.9    0.2 to 0.9    0.2 IU/day/kg, P < 0.01 vs. @entity8 ). CONCLUSIONS: Transplantation of UC-MSC and aBM-MNC was safe and associated with moderate improvement of metabolic measures in @entity1 with established @entity1723 .

Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on XXXX Secretion.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity1723 :: ('MESH:D003922', 'Disease') :: ['T1D', 'type 1 diabetes'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2690 :: (3630,Gene) :: ['Insulin']
